drugset / Trial / NCT01269411
RO4929097 in Treating Patients With Recurrent Invasive Gliomas
NaSingle-groupOpen-labelTreatment
Summary
This phase I trial is studying the side effects and best dose of RO4929097 in treating patients with recurrent invasive gliomas. RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
Timeline
- Start
- 2011-07
- Primary completion
- 2012-02
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RG4733 | Small molecule | — | Oral |